Related Factors To Dyslipidemia And Evaluation Of Statin Drug Efficacy And Safety In Very Aged Patinets

Objective：Investigation of ultra-related factors in aged dyslipidemia and evaluate statindrug efficacy and safety.Methods：①S elect the standard in the People’s Liberation Army General Hospital,2008-2009hospitalization of the elderly aged over147cases of patients for the study.②Using lipid abnormalities associated factors on the questionnaire over very elderlylipid investigation, analysis of factors associated with dyslipidemia;③Reference ATP Ⅲ and2007China revised standard adult dyslipidemia PreventionGuide for dyslipidemia observed object type;④According to the survey data analysis correlation between dyslipidemia andcoronary heart disease and cerebral infarction;⑤Using simvastatin, pravastatin, atorvastatin for senior citizens aged overdyslipidemia treatment, observed three kinds of statin drug therapy efficacy and safety;⑥Using SPSS19.0statistical software for statistical data obtained.Results：①Feeding methods, BMI, high blood sugar, high blood pressure, liver and kidneydysfunction, smoking and alcohol consumption and ultra very elderly dyslipidemiacorrelated (P <0.05);②ATP Ⅲ criteria: dyslipidemia highest HC+high TG group, simple low minimumHDL-C group; dyslipidemia super-elderly patients with low-risk, intermediate-riskgroup, risk group composition ratio were0%,0%,100%;③CHD, dyslipidemia cerebral infarction group was higher than that of non-CHDgroup, non-super-elderly group of elderly patients with cerebral infarction (P <0.05);④After one month of treatment with simvastatin20mg group compared lipid indexes 10mg group improved significantly (P <0.05), group2months of treatment TC levelsbelow20mg10mg group (P <0.05).20mg group of patients a month dislipidaemia ratewas higher than10mg group (P <0.05),2months of treatment showed no significantdifference (P>0.05).20mg group2month high incidence of adverse reactions in the10mg group;⑤After one month of treatment with simvastatin40mg group compared lipid indexes20mg group improved significantly (P <0.05),2months of treatment was not statisticallysignificant (P>0.05improvement over20mg group). Patients a month40mg group andthe compliance rate was higher than20mg group (P <0.05),2months of treatment wasnot statistically significant (P>0.05);40mg group the first two months of adversereactions was higher than20mg group;⑥Treatment with atorvastatin20mg group after a month of each index lipids improvedsignificantly over the10mg group (P <0.05),2months of treatment difference was notstatistically significant (P>0.05).1month of treatment compliance rates and20mggroups was higher than10mg group (P <0.05),2months of treatment was notstatistically significant (P>0.05);10mg group a month incidence of adverse reactionshigher than5mg group;Conclusions:①Feeding methods, BMI, high blood sugar, high blood pressure, kidney function, liverfunction abnormalities, smoking and alcohol consumption and ultra very elderlydyslipidemia relevant;super-elderly with coronary heart disease, the higher the degree oflipid abnormalities in patients with cerebral infarction.②Ultra-short-term elderly with simvastatin20mg/d dose higher compliance rate,prolonged low dose effect on improving TG deviation,20mg/d dose higher adversereaction rate; short term pravastatin40mg/d dose standards higher rate, taking long20mg/d and40mg/d dose of lipid-lowering effect is tantamount to bad40mg/d dosehigher reaction rates; short term atorvastatin20mg/d dose higher compliance rate,long-term use10mg/d and10mg/d dose of lipid-lowering effect is no different, early adverse drug treatment higher incidence.